<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am</td>
<td>Registration</td>
</tr>
<tr>
<td>8:45 am</td>
<td>Welcome</td>
</tr>
<tr>
<td>9:00 am</td>
<td>Hemophilia-Related Syndromes</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Leukocyte Disorders</td>
</tr>
<tr>
<td>11:00 am</td>
<td>Break</td>
</tr>
<tr>
<td>12:15 pm</td>
<td>Bone Marrow Failure States</td>
</tr>
<tr>
<td>1:30 pm</td>
<td>Adjourn / Lunch</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Dr. Kantoff</td>
</tr>
<tr>
<td>3:15 pm</td>
<td>Dr. Daniels</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>Dr. Brodsky</td>
</tr>
<tr>
<td>5:15 pm</td>
<td>Adjourn</td>
</tr>
<tr>
<td>6:15 pm</td>
<td>Adjourn</td>
</tr>
<tr>
<td>7:00 pm</td>
<td>Dinner at The Harvard Club</td>
</tr>
<tr>
<td>8:00 pm</td>
<td>Concluding Remarks</td>
</tr>
</tbody>
</table>

*Note: Program changes/substitutions may be made without notice.
COURSE DESCRIPTION: Care for patients with solid tumors, hematologic malignancies, and benign hematologic disorders continues to evolve with the development of novel therapeutic agents and testing modalities, accumulation of clinical trial data, and ongoing revisions to expert guidelines. Oncologists, hematologists, and other clinicians who participate in the care of patients with these disorders are challenged to stay current on the latest diagnosis, treatment, and management advances. This intensive six-day course provides a comprehensive review of the clinical, molecular, and pathophysiologic basis for the diagnosis and treatment of neoplastic diseases and benign hematologic conditions. Primary emphasis will be placed on the broad area of medical management within a multidisciplinary environment. Recent advances in molecular genetics, clinical pharmacology, epidemiology, and supportive care will be stressed. Teaching will be primarily through lectures, panels, and case discussions with the assistance of appropriate visual aids.

COURSE OBJECTIVES: Upon completion of this course, participants will be able to:

- Incorporate new and emerging clinical data into expert recommended best practices for diagnosis, evaluating, and treating patients with breast cancer
- Develop personalized treatment strategies for patients with lung, head and neck cancers, based on appropriate molecular testing and incorporating newly approved systemic therapies when appropriate
- Choose from available systemic agents as part of multimodal treatment approaches for patients with gastrointestinal and neuroendocrine cancers based on current molecular testing and risk assessment methods
- Develop treatment plans for prostate, testicular, renal, and bladder cancers that are tailored to individual patients’ risk factors and characteristics
- Create evidence-based care plans for patients with ovarian, cervical, endometrial, and trophoblastic cancers that incorporate recent advances in diagnosis and management
- Update treatment practices in a wide range of less common cancers, including Germ cell tumors, thyroid cancer, melanoma, sarcoma, and mesothelioma, based on emerging clinical evidence and current expert recommendations
- Develop evidence-based management plans for patients with benign hematologic disorders, incorporating new diagnostic strategies and novel therapies into current treatment paradigms
- Create optimized supportive care and survivorship plans for patients with cancer that take into account recent guidelines and current expert recommendations. Course objectives are reviewed annually with the faculty for currency and relevance and refined as necessary by the Course Director and selected physician advisors.

WHO SHOULD ATTEND: The course is directed to specialty physicians.

ACCREDITATION: The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Harvard Medical School designates this live activity for a maximum of 45.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Risk Management: This activity meets the criteria of the Massachusetts Board of Registration in Medicine for 75 credits of Risk Management Study. Please check your individual state licensing board guidelines and current expert recommendations for information and exercise their best professional judgment. Practitioners should always consult additional sources of evidence-based practice.

IOM COMPETENCIES: This course is designed to enhance the following American Board of Medical Specialties and Accreditation Council of Graduate Medical Education competencies: patient care and procedural skills, medical knowledge, practice-based learning and improvement, interpersonal and communication skills, professionalism, systems-based practice.

ABMS/ACGME COMPETENCIES: This course is designed to enhance the following American Board of Medical Specialties and Accreditation Council of Graduate Medical Education competencies: patient care and procedural skills, medical knowledge, practice-based learning and improvement, interpersonal and communication skills, professionalism, systems-based practice.

REGISTRATION INFORMATION:

- Physician fee: $1,600.00
- Residents and fellows in training: $1,600.00
- Allied Health Professionals: $1,600.00
- Early Registration Discount Rate: $1,350.00 (Early Registration Deadline: May 31, 2017)

Registration by credit card (VISA, MasterCard or American Express) can be made at www.hms-cme.net/732059-1801. Registrations for Harvard Medical School CME programs are made via our secure online registration system. To register for this course, please visit the course website. At the end of the registration process, a Processing (non-refundable service fee) $5 will be added to your registration fee, and you will have the choice of paying by check or credit card (Visa, MasterCard, or American Express). If you are paying by check, the online registration system will provide you with instructions and a printable form for remitting your course fees by check. Postal, telephone, fax, and cash-payment registrations are not accepted. Upon receipt of your paid registration, an email confirmation from the HMS DCE office will be sent to you.

Be sure to include an email address that you check frequently. Your email address is used for critical information, including confirmation registration, evaluation, and certificate. All fees shown in USD.

INQUIRIES: By phone (617-384-8600), Mon. – Fri. 9 am to 5 pm (ET) or by email at: ceprograms@mgh.harvard.edu

DISCLOSURE POLICY: Harvard Medical School (HMS) adheres to all ACCME Accreditation Criteria and Policies. It is HMS’s policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.

REFUND POLICY: Refunds, less an administrative fee of $75, will be issued for all cancellations received two weeks prior to the start of the course. Refund requests must be received by postal mail, email, or fax. No refund will be issued should cancellation occur less than two weeks prior. ‘No shows’ are subject to the full course fee and no refunds will be issued once the conference has started.

ACCOMMODATIONS/TRAVEL: A limited number of rooms has been reserved at the Fairmont Copley Plaza Hotel, 138 St. James Avenue, Boston, MA 02116. (Telephone: 617-267-5300) until September 2, 2017. Please specify that you are enrolled in this course to receive a conference rate. Hotels arrangements can also be made online at: https://resweb.passkey.com/go/dxi. Please do not purchase nonrefundable airline ticket(s) until you have received an email from our office confirming your paid registration.

DISCLAIMER: CME activities sponsored by Harvard Medical School are offered solely for educational purposes and do not constitute any form of certification of competency. Practitioners should always consult additional sources of information and exercise their best professional judgment before making clinical decisions of any kind.

FACULTY:

- Janet L. Abraham, MD
- Jeremy S. Abramson, MD
- Kenneth C. Anderson, MD
- Tracy T. Batchelor, MD, MPH
- Kenneth A. Bauer, MD
- James E. Bradner, MD
- Robert A. Brody, MD
- Harold J. Burstein, MD, PhD
- John C. Byrd, MD
- George P. Cannollos, MD
- Stephen A. Cannistra, MD
- Tony K. Choueiri, MD
- Jean M. Connors, MD
- Gilbert H. Daniels, MD
- Daniel J. DeAngelis, MD, PhD
- George D. Demetri, MD
- Walter H. Dzik, MD
- Peter C. Enzinger, MD
- Mark D. Fleming, MD, PhD
- David J. Fisch, MD
- Judy E. Garber, MD, MPH
- James D. Griffin, MD
- Robert H. Haddad, MD
- Robert H. Handin, MD
- Matthew M. Heerney, MD
- F. Stephen Hodi, MD
- Nicolas C. Isha, MD
- Pasi A. Jänne, MD, PhD
- Bruce E. Johnson, MD
- Philip W. Kantoff, MD
- Robert J. Kudner, MD
- David J. Kuter, MD, DPhil
- Ann S. LaCasce, MD
- Patrick J. Leierer, Sr, MD
- Ursula A. Marutlians, MD
- Robert J. Mayer, MD
- Ellis J. Neufeld, MD, PhD
- William K. Oh, MD
- Ari C. Parsons, B.Ch.
- Ann H. Partridge, MD, MPH
- David P. Ryan, MD
- Lecia V. Sequist, MD
- Geoffrey I. Shapiro, MD, PhD
- Alice T. Shaw, MD, PhD
- Robert J. Soiffer, MD
- David P. Steensma, MD
- Richard M. Stone, MD
- Sapna Syngal, MD, MPH
- Ayalew Tefferi, MD
- Nikhil Wagle, MD
- Eric P. Winer, MD

CANCER MEDICINE AND HEMATOLOGY

September 24–29, 2017 • Sunday–Friday
The Fairmont Copley Plaza Hotel
Boston, MA

For more information and registration:
www.hms-cme.net/732059-1801
COURSE DESCRIPTION: Care for patients with solid tumors, hematologic malignancies, and benign hematologic disorders continues to evolve with the development of novel therapeutic agents and testing modalities, accumulation of clinical trial data, and ongoing revisions to expert guidelines. Oncologists, hematologists, and other clinicians who participate in the care of patients with these disorders are challenged to stay current on the latest diagnosis, treatment, and management advances. This intensive six-day course provides a comprehensive review of the clinical, molecular, and pathophysiologic basis for the diagnosis and treatment of neoplastic diseases and benign hematologic conditions. Primary emphasis will be placed upon the broad area of medical management within a multidisciplinary environment. Recent advances in molecular genetics, clinical pharmacology, epidemiology, and supportive care will be stressed. Teaching will be primarily through lectures, panels, and case discussions with the assistance of appropriate visual aids.

COURSE OBJECTIVES: Upon completion of this course, participants will be able to:
- Incorporate new and emerging clinical data into expert recommended best practices for diagnosis, evaluating, and treating patients with breast cancer
- Develop personalized treatment strategies for patients with lung, head and neck cancers, based on appropriate molecular testing and incorporating newly approved systemic therapies when appropriate
- Choose from available systemic agents as part of multimodal treatment approaches for patients with gastrointestinal and neuroendocrine cancers based on current molecular testing and risk assessment methods
- Develop treatment plans for prostate, testicular, renal, and bladder cancers that are tailored to individual patients’ risk factors and characteristics
- Create evidence-based care plans for patients with ovarian, cervical, endometrial, and trophoblastic cancers that incorporate recent advances in diagnosis and management
- Update treatment practices in a wide range of less common cancers, including head and neck, thyroid, breast, melanoma, sarcoma, and mesothelioma, based on emerging clinical evidence and current expert recommendations
- Develop evidence-based management plans for patients with benign hematologic disorders, incorporating new diagnostic strategies and novel therapies into current treatment paradigms
- Create optimized supportive care and survivorship plans for patients with cancer that take into account recent guidelines and current expert recommendations. Course objectives are reviewed annually with the faculty for currency and relevance and refined as necessary by the Course Director and selected physician advisors.

WHO SHOULD ATTEND: The course is directed to specialty physicians.

ACCREDITATION: The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Harvard Medical School designates this live activity for a maximum of 45AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Risk Management: This activity meets the criteria of the Massachusetts Board of Registration in Medicine for 75 credits of Risk Management Study.

Please check your individual state licensing board requirements before claiming these credits.

Incorporation of new and emerging clinical data into expert-recommended best practices for diagnosis, evaluating, and treating patients with breast cancer.

Course Director and selected physician advisors.

DISCLOSURE POLICY: Harvard Medical School (HMS) adheres to all ACCME Accreditation Criteria and Policies. It is HMS policy that those who have influenced the content of a CME activity (e.g., planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to review any limitations of data and unlabeled or investigational uses of products during their presentations.

REFUND POLICY: Refunds, less an administrative fee of $75, will be issued for all cancellations received two weeks prior to the start of the course. Refund requests must be received by postal mail, email, or fax. No refund will be issued should cancellation occur less than two weeks prior. “No shows” are subject to the full course fee and no refunds will be issued once the course has started.

ACCOMMODATIONS/TRAVEL: A limited number of rooms has been reserved at the Fairmont Copley Plaza Hotel, 138 St. James Avenue, Boston, MA 02116 (Telephone: 617-267-5300) until September 2, 2017. Please specify that you are enrolled in this course to receive a conference rate. Hotel arrangements can also be made online at: https://resweb.passkey.com/go/dcfi. Please do not purchase nonrefundable airline tickets until you have received an email from our office confirming your paid registration.

DISCLAIMER: CME activities sponsored by Harvard Medical School are offered solely for educational purposes and do not constitute any form of certification of competency. Practitioners should always consult additional sources of information and exercise their best professional judgment before making clinical decisions of any kind.

FACULTY:
- Janet L. Abraham, MD
- Jeremy S. Abramson, MD
- Kenneth C. Anderson, MD
- Tracy T. Batchelor, MD, MPH
- Kenneth A. Bauer, MD
- James E. Brashear, MD
- Robert A. Brodsky, MD
- Harold J. Burstein, MD, PhD
- John C. Byrd, MD
- George P. Cannon, MD
- Stephen A. Cassinistra, MD
- Tony K. Choueiri, MD
- Jean M. Conners, MD
- Gilbert H. Daniels, MD
- Daniel J. DeAngelo, MD, PhD
- George D. Demetri, MD
- Walter H. Dizik, MD
- Peter C. Enzinger, MD
- Mark D. Fleming, MD, PhD
- Arnold S. Freedman, MD
- Judy E. Garber, MD, MPH
- James D. Griffin, MD
- Robert I. Haddad, MD
- Robert I. Handin, MD
- Matthew M. Heerney, MD
- F. Stephen Hodi, MD
- Nicolas C. Iwasa, MD
- Pasi A. Jänne, MD, PhD
- Bruce E. Johnson, MD
- Philip W. Kantoff, MD
- Judy E. Garber, MD, MPH
- Geoffrey I. Shapiro, MD, PhD
- Alice T. Shaw, MD, PhD
- Robert I. Soffier, MD
- David P. Steensma, MD
- Richard M. Stone, MD
- Sapia Systag, MD, MPH
- Ayalew Telfert, MD
- Nikhil Wagle, MD
- Erica P. Winer, MD
- Kenneth Kaushansky, MD
- Ian E. Krop, MD
- Matthew H. Kulke, MD
- David J. Kuter, MD, DPhil
- Ann S. LaCasce, MD
- Patrick J. List, MD, MPH
- Ursula A. Marutlonis, MD
- Robert J. Mayer, MD
- Elvis J. Neufeld, MD, PhD
- William K. Oh, MD
- Aric D. Parmes, B.Ch.
- Ania K. Przuntek, MD, MPH
- David P. Ryan, MD
- Lecia V. Sequist, MD
- Geoffrey I. Shapiro, MD, PhD
- Alice T. Shaw, MD, PhD
- Robert I. Soffier, MD
- David P. Steensma, MD
- Richard M. Stone, MD
- Sapia Systag, MD, MPH
- Ayalew Telfert, MD
- Nikhil Wagle, MD
- Erica P. Winer, MD
COURSE DESCRIPTION: Care for patients with solid tumors, hematologic malignancies, and benign hematologic disorders continues to evolve as the development of new diagnostic therapeutic agents and testing modalities, accumulation of clinical trial data, and ongoing revisions to expert guidelines. Oncologists, hematologists, and other clinicians who participate in the care of patients with these disorders are challenged to stay current on the latest diagnosis, treatment, and management advances. This intensive six-day course provides a comprehensive overview of the clinical, molecular, and pathophysiological basis for the diagnosis and treatment of neoplastic diseases and benign hematologic conditions. Primary emphasis will be placed upon the broad area of neoplastic diseases and benign hematologic conditions. Further, the course will be designed to challenge participants to stay current on the latest diagnosis, treatment, and management advances. This intensive six-day course is designed to enhance the knowledge and skills of physicians who participate in the care of patients with these disorders, and to provide a comprehensive overview of the clinical, molecular, and pathophysiological basis for the diagnosis and treatment of neoplastic diseases and benign hematologic conditions. Primary emphasis will be placed upon the broad area of neoplastic diseases and benign hematologic conditions.

WHO SHOULD ATTEND: The course is directed to specialty physicians.

ACCREDITATION: The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Harvard Medical School designates this live activity for a maximum of 45.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Risk Management: This activity meets the criteria of the Massachusetts Board of Registration in Medicine for 75 credits of Risk Management Study.

Please check your individual state licensing board requirements before claiming these credits.

CME ACCREDITATION: This course is designed to enhance the following American Board of Medical Specialties and Accreditation Council of Graduate Medical Education competencies: patient care and procedural skills, medical knowledge, practice-based learning and improvement, interpersonal and communication skills, professionalism, systems-based practice.

ABMS/ACGME COMPETENCIES: This course is designed to enhance the following Institute of Medicine competencies: provide evidence-based practice.

REGISTRATION INFORMATION: Physicians fee: $1,600.00
Residents and Fellows in training: $1,600.00
Allied Health Professionals: $1,600.00
Early Registration Discount Rate: $1,550.00
(Effective Registration Deadline: May 31, 2017.)

Registration by credit card (VISA, MasterCard or American Express) can be made at www.hms-cme.net/720959-1801.

Refunds, less an administrative fee of $75, will be issued for all cancellations received two weeks prior to the start of the course. Refund requests must be received by postal mail, email, or fax. No refund will be issued if cancellation occurs less than two weeks prior to the start of the course. Refund requests must be received by postal mail, email, or fax. No refund will be issued if cancellation occurs less than two weeks prior to the start of the course. Refund requests must be received by postal mail, email, or fax. No refund will be issued if cancellation occurs less than two weeks prior to the start of the course.

ACCOMMODATIONS/TRAVEL: A limited number of rooms has been reserved at the Fairmont Copley Plaza Hotel, 138 St. James Avenue, Boston, MA 02116. (Telephone: 617-267-5300) until September 2, 2017. Please specify that you are enrolled in this course to receive a conference rate. Hotel arrangements can also be made online at: https://resweb.passkey.com/go/dcs. Please do not purchase nonrefundable airline tickets until you have received an email from our office confirming your paid registration.

DISCLAIMER: CME activities sponsored by Harvard Medical School are offered solely for educational purposes and do not constitute any form of certification of competency. Practitioners should always consult additional sources of information and exercise their best professional judgment before making clinical decisions of any kind.

FACULTY:

Janet L. Abraham, MD
Jeremy S. Abramson, MD
Kenneth C. Anderson, MD
Tracey T. Batchelor, MD, MPH
Kenneth A. Bauer, MD
James E. Bradley, MD
Robert A. Brodsky, MD
Harold J. Burstein, MD, PhD
John C. Byrd, MD
George P. Canellos, MD
Stephen A. Cannistra, MD
Toni K. Choueiri, MD
Jean M. Conners, MD
Gilbert H. Daniels, MD
Daniel J. DeAngelis, MD, PhD
George D. Demetri, MD
Walter H. Dzik, MD
Peter C. Enzinger, MD
Mark D. Fleming, MD, PhD
Arnold S. Freedman, MD
Judy E. Garber, MD, MPH
James D. Griffin, MD
Robert J. Haddad, MD
Robert L. Haindon, MD
Matthew M. Heeney, MD
F. Stephen Hodi, MD
Nicolas C. Issa, MD
Pas I. Janner, MD, PhD
Bruce E. Johnson, MD
Philip W. Kantoff, MD
Harold J. Burstein, MD, PhD
John C. Byrd, MD
George P. Canellos, MD
Stephen A. Cannistra, MD
Toni K. Choueiri, MD
Jean M. Conners, MD
Gilbert H. Daniels, MD
Daniel J. DeAngelis, MD, PhD
George D. Demetri, MD
Walter H. Dzik, MD
Peter C. Enzinger, MD
Mark D. Fleming, MD, PhD
Arnold S. Freedman, MD
Judy E. Garber, MD, MPH
James D. Griffin, MD
Robert J. Haddad, MD
Robert L. Haindon, MD
Matthew M. Heeney, MD
F. Stephen Hodi, MD
Nicolas C. Issa, MD
Pas I. Janner, MD, PhD
Bruce E. Johnson, MD
Philip W. Kantoff, MD
Karen A. Kaushansky, MD
Ian E. Krop, MD
Matthew H. Kulke, MD
David J. Kuter, MD, DPhil
Ann S. LaCasce, MD
Patrick J. Laweher, Sr. MD
Ursula A. Maruyama, MD
Robert J. Mayer, MD
Elia J. Neufeld, MD, PhD
William K. Oh, MD
Aric D. Parnes, BCSc
Ann H. Partridge, MD, MPH
David P. Ryan, MD
Leila V. Sequist, MD
Geoffrey I. Shapiro, MD, PhD
Jeffrey L. Shapiro, MD, PhD
Alice T. Shaw, MD, PhD
Robert J. Soiffer, MD
David P. Steensma, MD
Richard M. Stone, MD
Sapna Syngal, MD, MPH
Ayalew Tefferi, MD
Nikhil Vagle, MD
Eric P. Winer, MD

INQUIRIES:

For more information and registration: www.hms-cme.net/720959-1801

The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This course is designed to enhance the following American Board of Medical Specialties and Accreditation Council of Graduate Medical Education competencies: patient care and procedural skills, medical knowledge, practice-based learning and improvement, interpersonal and communication skills, professionalism, systems-based practice.

ABMS/ACGME COMPETENCIES: This course is designed to enhance the following Institute of Medicine competencies: provide evidence-based practice.

REGISTRATION INFORMATION: Physicians fee: $1,600.00
Residents and Fellows in training: $1,600.00
Allied Health Professionals: $1,600.00
Early Registration Discount Rate: $1,550.00
(Effective Registration Deadline: May 31, 2017.)

Registration by credit card (VISA, MasterCard or American Express) can be made at www.hms-cme.net/720959-1801.

Refunds, less an administrative fee of $75, will be issued for all cancellations received two weeks prior to the start of the course. Refund requests must be received by postal mail, email, or fax. No refund will be issued if cancellation occurs less than two weeks prior to the start of the course. Refund requests must be received by postal mail, email, or fax. No refund will be issued if cancellation occurs less than two weeks prior to the start of the course. Refund requests must be received by postal mail, email, or fax. No refund will be issued if cancellation occurs less than two weeks prior to the start of the course.

ACCOMMODATIONS/TRAVEL: A limited number of rooms has been reserved at the Fairmont Copley Plaza Hotel, 138 St. James Avenue, Boston, MA 02116. (Telephone: 617-267-5300) until September 2, 2017. Please specify that you are enrolled in this course to receive a conference rate. Hotel arrangements can also be made online at: https://resweb.passkey.com/go/dcs. Please do not purchase nonrefundable airline tickets until you have received an email from our office confirming your paid registration.

DISCLAIMER: CME activities sponsored by Harvard Medical School are offered solely for educational purposes and do not constitute any form of certification of competency. Practitioners should always consult additional sources of information and exercise their best professional judgment before making clinical decisions of any kind.

FACULTY:

Janet L. Abraham, MD
Jeremy S. Abramson, MD
Kenneth C. Anderson, MD
Tracey T. Batchelor, MD, MPH
Kenneth A. Bauer, MD
James E. Bradley, MD
Robert A. Brodsky, MD
Harold J. Burstein, MD, PhD
John C. Byrd, MD
George P. Canellos, MD
Stephen A. Cannistra, MD
Toni K. Choueiri, MD
Jean M. Conners, MD
Gilbert H. Daniels, MD
Daniel J. DeAngelis, MD, PhD
George D. Demetri, MD
Walter H. Dzik, MD
Peter C. Enzinger, MD
Mark D. Fleming, MD, PhD
Arnold S. Freedman, MD
Judy E. Garber, MD, MPH
James D. Griffin, MD
Robert J. Haddad, MD
Robert L. Haindon, MD
Matthew M. Heeney, MD
F. Stephen Hodi, MD
Nicolas C. Issa, MD
Pas I. Janner, MD, PhD
Bruce E. Johnson, MD
Philip W. Kantoff, MD
Karen A. Kaushansky, MD
Ian E. Krop, MD
Matthew H. Kulke, MD
David J. Kuter, MD, DPhil
Ann S. LaCasce, MD
Patrick J. Laweher, Sr. MD
Ursula A. Maruyama, MD
Robert J. Mayer, MD
Elia J. Neufeld, MD, PhD
William K. Oh, MD
Aric D. Parnes, BCSc
Ann H. Partridge, MD, MPH
David P. Ryan, MD
Leila V. Sequist, MD
Geoffrey I. Shapiro, MD, PhD
Jeffrey L. Shapiro, MD, PhD
Alice T. Shaw, MD, PhD
Robert J. Soiffer, MD
David P. Steensma, MD
Richard M. Stone, MD
Sapna Syngal, MD, MPH
Ayalew Tefferi, MD
Nikhil Vagle, MD
Eric P. Winer, MD

INQUIRIES: By phone (617-384-8600), Mon. – Fri. 9 am to 5 pm (EST) or by email at: ceprogram@hms.harvard.edu.

INQUIRIES: By phone (617-384-8600), Mon. – Fri. 9 am to 5 pm (EST) or by email at: ceprogram@hms.harvard.edu.
COURSE DESCRIPTION: Care for patients with solid tumors, hematologic malignancies, and benign hematologic disorders continues to evolve with the development of novel therapeutic agents and testing modalities, accumulation of clinical trial data, and ongoing revisions to expert guidelines. Oncologists, hematologists, and other clinicians who participate in the care of patients with these disorders are challenged to stay current on the latest diagnosis, treatment, and management advances. This intensive six-day course provides a comprehensive review of the clinical molecular and pathophysiological basis for the diagnosis and treatment of neoplastic diseases and benign hematologic conditions. Primary emphasis will be placed on the broad area of medical management within a multidisciplinary environment. Recent advances in molecular genetics, clinical pharmacology, epidemiology, and supportive care will be stressed. Teaching will be primarily through lectures, panels, and case discussions with the assistance of appropriate visual aids.

COURSE OBJECTIVES: Upon completion of this course, participants will be able to:

- Incorporate new and emerging clinical data into expert recommended best practices for diagnosis, evaluating, and treating patients with breast cancer.
- Develop personalized treatment strategies for patients with lung, head and neck cancers, based on appropriate molecular testing and incorporating newly approved systemic therapies when appropriate.
- Choose from available systemic agents as part of multimodal treatment approaches for patients with gastrointestinal and neuroendocrine cancers based on current molecular testing and risk assessment methods.
- Develop treatment plans for prostate, testicular, renal, and bladder cancers that are tailored to individual patients’ risk factors and characteristics.
- Create evidence-based care plans for patients with ovarian, cervical, endometrial, and trophoblastic cancers that incorporate recent advances in diagnosis and management.
- Update treatment practices in a wide range of less common cancers, including follicular lymphoma, thyroid cancer, melanoma, sarcoma, and mesothelioma, based on emerging clinical evidence and current expert recommendations.
- Develop evidence-based management plans for patients with benign hematologic disorders, incorporating new diagnostic strategies and novel therapies into current treatment paradigms.
- Create optimized supportive care and survivorship plans for patients with cancer that take into account recent guidelines and current expert recommendations. Course objectives are reviewed annually with the faculty for currency and relevance and refined as necessary by the Course Director and selected physician advisors.

WHO SHOULD ATTEND: The course is directed to specialty physicians.

ACCREDITATION: The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Harvard Medical School designates this live activity for a maximum of 45 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Risk Management: This activity meets the criteria of the Massachusetts Board of Registration in Medicine for 54 credits of Risk Management Study. Please check your individual state licensing board requirements before claiming these credits.

Through an agreement between the American Medical Association and the European Union of Medical Specialists, physicians may convert AMA PRA Category 1 Credits™ to an equivalent number of European CME Credits® (ECMECs®). Information on the process of converting AMA PRA Category 1 Credits™ to ECMECs® can be found at: www.eacme.eu.

AMBS/ACMG COMPETENCIES: This course is designed to enhance the following American Board of Medical Specialties and Accreditation Council of Graduate Medical Education competencies: patient care and procedural skills, medical knowledge, practice-based learning and improvement, interpersonal and communication skills, professionalism, systems-based practice.

IOM COMPETENCIES: This course is designed to enhance the following Institute of Medicine competencies: provide patient-centered care, work in interdisciplinary teams, employ evidence-based practice.

REGISTRATION INFORMATION:

**Physician fee** .......................................................... $1,600.00
Residents and Fellows in training ........................................ $1,100.00
Allied Health Professionals ............................................. $1,600.00
Early Registration Discount Rate .............................. $1,550.00
(Effective Registration Deadline: May 31, 2017)

Registration by credit card (VISA, MasterCard or American Express) can be made at www.hms-cme.net/732059-1801.

Registrations for Harvard Medical School CME programs are made via our secure online registration system. To register for this course, please visit the course website. At the end of the registration process, a Processing (non-refundable service fee) $5 will be added to your registration. If you are paying by check, the online registration system will provide you with instructions and a printable form for remitting your course fees by check. Postal, telephone, fax, and cash-payment registrations are not accepted. Upon receipt of your paid registration, an email confirmation from the HMS DICE office will be sent to you.

Be sure to include an email address that you check frequently. Your email address is used for critical information, including registration confirmation, evaluation, and certificate. All fees shown in USD.

INQUIRIES: By phone (617-384-8600), Mon. – Fri. 9 am to 5 pm (ET) or by email at: ceprogram@hms.harvard.edu.

DISCLOSURE POLICY: Harvard Medical School (HMS) adheres to all ACCME Accreditation Criteria and Policies. It is our policy to share with those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to exercise any limitations of data and unlabeled or investigational uses of products during their presentations.

REFUND POLICY: Refunds, less an administrative fee of $75, will be issued for all cancellations received two weeks prior to the start of the course. Refund requests must be received by postal mail, email, or fax. No refund will be issued should cancellation occur less than two weeks prior to the course. "No shows" are subject to the full course fee and no refunds will be issued once the course has started.

ACCOMMODATIONS/TRAVEL: A limited number of rooms has been reserved at the Fairmont Copley Plaza Hotel, 138 St. James Avenue, Boston, MA 02116. (Telephone: 617-267-5300) until September 2, 2017. Please specify that you are enrolled in this course to receive a conference rate. Hotel arrangements can also be made online at: https://resweb.passkey.com/go/dxci. Please do not purchase nonrefundable airline ticket(s) until you have received an email from our office confirming your paid registration.

DISCLAIMER: CME activities sponsored by Harvard Medical School are offered solely for educational purposes and do not constitute any form of certification of competency. Practitioners should always consult additional sources of information and exercise their best professional judgment before making clinical decisions of any kind.

FACULTY:

Janet L. Abraham, MD
Jeremy S. Abramson, MD
Kenneth C. Anderson, MD
Tracey T. Batchelor, MD, MPH
Kenneth A. Bauer, MD
James E. Bradner, MD
Robert A. Brodsky, MD
Harold J. Burstein, MD, PhD
John C. Byrd, MD
George P. Cannollis, MD
Stephen A. Cannistra, MD
Toni K. Choueiri, MD
Jean M. Conners, MD
Gilbert H. Daniels, MD
Daniel J. DeAngelis, MD, PhD
George D. Demetri, MD
Walter H. Dzik, MD
Peter C. Enzinger, MD
Mark D. Fleming, MD, PhD
Arnold S. Freedman, MD
Judy E. Garber, MD, MPH
James D. Griffin, MD
Robert I. Haddad, MD
Robert I. Handin, MD
Matthew M. Heeney, MD
Fred Stephen Hodi, MD
Nicolas C. Issa, MD
Paul A. Janner, MD, PhD
Bruce E. Johnson, MD
Philip W. Kantoff, MD
Harold J. Burstein, MD, PhD
Kenneth Kaushansky, MD
Ian E. Krop, MD
Matthew H. Kulke, MD
David J. Kuter, MD, DPhil
Ann S. LaCasce, MD
Patrick J. Luehrer, Sr, MD
Ursula A. Marutulos, MD
Robert J. Mayer, MD
Elis J. Neufeld, MD, PhD
William K. Oh, MD
Arc D. Parne, B.Ch.
Ann H. Partridge, MD, MPH
David P. Ryan, MD
Lecia V. Sequist, MD
Geoffrey I. Shapiro, MD, PhD
Alice T. Shaw, MD, PhD
Robert J. Soiffer, MD
David P. Steensma, MD
Richard M. Stone, MD
Sapna Syngal, MD, MPH
Ayalew Tefferi, MD
Nicki Hag,Wigle, MD
Eric P. Winer, MD

CANCER MEDICINE AND HEMATOLOGY

September 24-29, 2017 • Sunday–Friday
The Fairmont Copley Plaza Hotel
Boston, MA

For more information and registration: www.hms-cme.net/732059-1801
SCHEDULE CANCER MEDICINE AND HEMATOLOGY 2017

EVENING REGISTRATION 5:30 – 8:30 PM
SUNDAY, SEPTEMBER 24

Presiding: Dr. Mayer
7:00 am Registration
8:45 am Welcome Dr. Mayer
9:00 am Hemophilia-Related Syndromes Dr. Neufeld
10:00 am Leukocyte Disorders Dr. Parnes
11:00 am Break
11:15 am Hemolytic Anemias Dr. Connors
12:15 pm Bone Marrow Failure States Dr. Brodsky
1:15 pm Adjourn / Lunch

Presiding: Dr. Mayer
2:15 pm Thrombocytopenias Dr. Kaushansky
3:15 pm Hypersplenism and Iron Overload Dr. Fleming
4:00 pm Break
4:15 pm Hemoglobinopathies Dr. Heeney
5:15 pm Advances in Cancer Drug Development Dr. Shapiro
6:15 pm Adjourn

MONDAY, SEPTEMBER 25

Presiding: Dr. Mayer
8:00 am Platelet Function and von Willebrand’s Disease Dr. Handlin
9:00 am Hypercoagulable Syndromes and New Anticoagulant Therapies Dr. Bauer
10:15 am Break
10:30 am Stem Cell Biology and Hematopoietic Growth Factors Dr. Kuter
11:30 am Panel Discussion (Drs. Bauer, Handlin, Kuter)
12:00 pm Lunch

Presiding: Dr. Kuter
1:00 pm Molecular Genetics of Cancer Transfusion Medicine for the Clinician Dr. Wagle
2:00 pm Infections in the Immunocompromised Host Dr. Issa
4:00 pm Biology of Bone Marrow Transplantation Dr. Soffer
5:00 pm Adjourn

TUESDAY, SEPTEMBER 26

Presiding: Dr. Stone
8:00 am Plasma Cell Neoplasms Dr. Anderson
9:00 am Myelodysplasia Dr. Steinmeyer
9:45 am Acute Myeloid Leukemia Dr. Stone
10:45 am Break

Presiding: Dr. DeAngelis
11:00 am Chronic Myeloid Leukemia Dr. DeAngelis
11:45 am Myeloproliferative Syndromes Dr. Telfer
12:30 pm Panel Discussion (Drs. Anderson, DeAngelis, Steinmeyer, Stone, Telfer)
1:00 pm Lunch

Presiding: Dr. Stone
2:00 pm Low Grade Lymphoma Dr. Abramson
2:40 pm High Grade Lymphoma Dr. Friedman
3:30 pm Break
3:45 pm Hodgkin Lymphoma Dr. Lachapelle
4:30 pm CLL and Variants Dr. Byrd
5:15 pm Panel Discussion (Drs. Abramson, Byrd, Friedman, Lachapelle)
5:45 pm Adjourn

LUNCH

Presiding: Dr. Stone
7:00 – 9:30 pm 2017 ABIM Maintenance of Certification (MOC) Module Drs. Burstein, DeAngelis

*Scheduling changes and substitutions may be made without notice.

MONDAY, SEPTEMBER 25

Presiding: Dr. Mayer
8:00 am Thrombocytopenias Dr. Kaushansky
3:15 pm Iron Deficiency and Iron Overload Dr. Fleming
4:00 pm Break
4:15 pm Hemoglobinopathies Dr. Heeney
5:15 pm Advances in Cancer Drug Development Dr. Shapiro
6:15 pm Adjourn

THURSDAY, SEPTEMBER 28

Presiding: Dr. Winer
Breast Cancer Lunch
8:00 am Survivorship Issues in Breast Cancer and Other Malignancies Dr. Partridge
9:00 am Breast Cancer: Risk, Genetics and Prevention Dr. Garber
9:35 am Pre-Invasive Disease, Surgery, Radiation, Hematologic Therapy Dr. Burstein
10:15 am Break
10:30 am Adjunct and Neoadjuvant Therapy Dr. Winer
11:15 am Miscellaneous Dr. Krop
11:50 am Panel Discussion (Drs. Burstein, Garber, Krop, Partridge, Winer)
12:30 pm Concluding Remarks Dr. Mayer
12:45 pm Adjourn

CANCER MEDICINE AND HEMATOLOGY
September 24-29, 2017
Sunday-Friday
The Fairmont Copley Plaza Hotel Boston, MA

OFFERED BY Dana Farber/Partners CancerCare

COURSE DIRECTOR Robert J. Mayer, MD